



RECEIVED  
SEP 04 2003  
TECH CENTER 1600/2900

REMARKS/ARGUMENTS

Reconsideration of this application is requested. Claims 67-76 and 85 are pending in the application subsequent to entry of this amendment.

Responding to items 1 and 2 of the Official Action, claim 85 has been amended to delete those structures for A<sub>1</sub> which are not within the elected subject matter. Thus applicants' claims are directed to compounds in which A<sub>1</sub> is a benzothiazepene, benzoxazepine and dibenzoxazepine.

With regard to the remaining unresolved issues presented in the Official Action, applicants comment as follows.

With regard to Item 6, "growth hormone" is mentioned on page 28, line 13 of the specification. Please see the attachment.

With regard to Item 8a, Example Nos. 67 and 68 on page 45 relate to 1,4-dioxo-2,3-dihydro-benzo[1,5]thiazepine.

With regard to item 8b, Example NO. 172 has the structure: -NH-CH<sub>2</sub>-CH(OH)-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH(OH)-CH<sub>3</sub>.

The amendments to claim 85 were discussed with examiner Coleman and it is counsel's understanding that the choices for A<sub>1</sub> reflect the searched and examined subject matter, for instance is identified in the Official Action of October 29, 2002, paper No. 13, page 3, lines 6-8 and as summarized above.


If for any reason this amendment does not place all claims in condition for allowance the examiner is encouraged to contact the undersigned by telephone.

FUNAMIZU et al  
Appl. No. 09/485,845  
September 2, 2003

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



Arthur R. Crawford  
Reg. No. 25,327

ARC:pfc  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100